Here below are the publications (1) participated by Alberto Moriggia using the term string compromise (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations).
Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch
Alberto Moriggiais currently collaborating with
Fondazione Epatocentro Ticino (Rif. FET)
Via Soldino, 9
6962 Lugano
Alberto Moriggia
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Hepatitis C Virus HCV - A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection (D3FEAT) (Rif. 10000 202407)
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Hepatitis C Virus HCV - A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection (D3FEAT) (Rif. 10000 202407)
Alberto Moriggia
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Hepatitis C Virus HCV - Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection (REACT) (Rif. 40000 202407)
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Hepatitis C Virus HCV - Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection (REACT) (Rif. 40000 202407)
Alberto Moriggia
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Statoepatite non alcolica NASH - Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (STELLAR 3) (Rif. 50000 202407)
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Statoepatite non alcolica NASH - Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (STELLAR 3) (Rif. 50000 202407)
Alberto Moriggia
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Statoepatite non alcolica NASH - Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR 4) (Rif. 55000 202407)
on behalf of
Fondazione Epatocentro Ticino (Rif. FET)
is currently Research Program Leader [Rif. 50110] for
Statoepatite non alcolica NASH - Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR 4) (Rif. 55000 202407)